Search BCYC
BICYCLE THERAPEUTICS PLC
Nasdaq · CIK 1761612
Last close3.38
Daily change-0.18 (-5.06%)
10 Years gain-71.83%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BCYC · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
42.7Momentum
0.0Acceleration
13.0Confidence
91.0Annual Revenue9
Quarterly Revenue31
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality8.6 / 25
Capital Efficiency1.8 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 1172.0307 percentage points.
ROIC declining · MEDIUMROIC declined by 3.4926 percentage points.
Key Metrics
Revenue Growth TTM-61.08%OK
Revenue CAGR 3Y71.21%OK
Gross Margin100%OK
Operating Margin-1,683.33%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-58.08%OK
Incremental Operating Margin 3Y-10,250.28%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.88%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $72.59M | $72.59M | -$247.07M | -$249.68M | -$252.03M | 100% | -340.38% | -347.21% | n/a | 69.28M |
| 2025 FY Dec 31, 2024 | $35.28M | $35.28M | -$209.87M | -$164.72M | -$165.96M | 100% | -594.96% | -470.47% | n/a | 58.21M |
| 2025 FY Dec 31, 2023 | $26.98M | $26.98M | -$189.95M | -$60.63M | -$63.56M | 100% | -704.13% | -235.61% | n/a | 35.59M |
| 2024 FY Dec 31, 2022 | $14.46M | $14.46M | -$116.65M | -$86.11M | -$105.10M | 100% | -806.56% | -726.67% | n/a | 29.66M |
| 2023 FY Dec 31, 2021 | $11.70M | $11.70M | -$65.62M | -$14.79M | -$16.82M | 100% | -560.98% | -143.83% | -218.67% | 25.06M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $16.17M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-088457, 0001104659-25-104010 |
| Revenue Growth TTM | -61.08% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-088457, 0001104659-25-104010 |
| Revenue CAGR 3Y | 71.21% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-028971 |
| Revenue CAGR 5Y | 47.52% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-028971 |
| Gross Profit CAGR 3Y | 71.21% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-028971 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-088457, 0001104659-25-104010 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001104659-26-088457, 0001104659-25-104010 |
| Operating Margin | -1,683.33% | Operating Income / Revenue | OK | 0001104659-26-088457, 0001104659-25-104010 |
| ROIC | -58.08% | NOPAT / Average Invested Capital | OK | 0001104659-26-088457, 0001104659-25-104010 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-088457 |
| Current Ratio | 12.08x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.23 | Revenue / Diluted Shares | OK | 0001104659-26-088457, 0001104659-25-104010 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |